Oct 23 (Reuters) - NPS Pharmaceuticals Inc said the U.S. Food and Drug Administration had extended the review date for its hormone replacement therapy by three months to provide time for a full...
NPS Pharmaceuticals NPSP raised $50 million Monday through the sale of its Preotact royalty stream to Drug Royalty Corporation. We're maintaining our
Pharmaceuticals International, Inc. (U.S. Shares) (2.19%), AstraZeneca PLC (ADR) (1.78%) and NPS Pharmaceuticals , Inc. (1.74%). There are no assurances that any Janus portfolio currently holds these securities or other
(Reuters) - U.S. drug reviewers found three serious concerns related to NPS Pharmaceuticals Inc's experimental drug for short bowel syndrome but said they did not think the drug needed to be...
We are no longer providing equity research on NPS Pharma NPSP . We provide broad coverage of more than 1,800 companies across 91 industry groups and adjust our coverage as necessary based on client demand and investor interest.
We're maintaining our fair value estimate for NPS Pharmaceuticals NPSP following the release of positive Phase III data for Gattex (teduglutide) for short bowel syndrome. The outcome is consistent
We're maintaining NPS Pharmaceuticals ' NPSP fair value estimate following an uneventful first-quarter earnings report. The company has a manageable cash burn rate and continues
As we approach NPS Pharmaceuticals ' NPSP fourth-quarter earnings report, we're looking for continued strong royalty revenue from Amgen AMGN and tight management of
NPS Pharmaceuticals ' NPSP loss of CEO Tony Coles to Onyx Pharmaceuticals ONXX, announced Tuesday, does not affect our fair value estimate for NPS. The
We may modestly reduce NPS Pharmaceuticals ' NPSP fair value estimate following the delay of its Gattex program for short bowel syndrome. The Food and Drug Administration (FDA